The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.
 
Katherine B. Peters
Consulting or Advisory Role - Abbvie; Agios; Boehringer Ingelheim; Eisai; Monteris Medical; Novocure
Research Funding - Abbvie; Agios; BioMimetix; Bristol-Myers Squibb; Monteris Medical
 
Gerald E. Archer
No Relationships to Disclose
 
Pamela Norberg
No Relationships to Disclose
 
Weihua Xie
No Relationships to Disclose
 
Stevie Threatt
No Relationships to Disclose
 
Eric S Lipp
No Relationships to Disclose
 
James Emmett Herndon
No Relationships to Disclose
 
Patrick Healy
No Relationships to Disclose
 
Kendra Congdon
No Relationships to Disclose
 
Luis Sanchez-Perez
No Relationships to Disclose
 
Henry S. Friedman
Leadership - Istari Oncology
Stock and Other Ownership Interests - 2x Oncology; ISTARI Oncology
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Letters of Patent for Oncolytic Poliovirus for Human Tumors
Travel, Accommodations, Expenses - Genentech/Roche
 
Annick Desjardins
Stock and Other Ownership Interests - ISTARI Oncology
Consulting or Advisory Role - Celgene; Genentech/Roche
Research Funding - Celldex (Inst); Genentech/Roche (Inst); Lilly (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Symphogen (Inst); Triphase Accelerator Corp (Inst)
Patents, Royalties, Other Intellectual Property - AU 2013347945 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CA 2,892,183 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; CN 201380070749.7 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; EP 13856989.2 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; HK 15112399.5 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent; JP 2015-544130 Div: 2017-084158 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, and a patent; PCT/US17/023148 - Combination Therapy for Cancer Using Oncolytic Poliovirus licensed to Istari and Stock options, ISTARI Oncology; US 15/428510 - Method of Treating Solid Tumor w/Oncolytic Poliovirus licensed to Istari, a patent
 
Gordana Vlahovic
Honoraria - Genentech/Roche; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Speakers' Bureau - Genentech/Roche; Pfizer
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Pfizer
 
John H. Sampson
Stock and Other Ownership Interests - Annias Immunotherapeutics; Immunomic Therapeutics; Insera Health; ISTARI; Neuronium
Honoraria - National Cancer Institute
Consulting or Advisory Role - Annias Immunotherapeutics; Bristol-Myers Squibb; Insera Health; Insera Health; Medicenna
Patents, Royalties, Other Intellectual Property - Annias Immunotherapeutics - Equity, Licensed IP; Celldex - Licensed IP, Royalties; Istari Oncology - Equity, Licensed IP; Neuronium - Equity, Optioned IP